Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome - Takeaways - MDSpire

Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome

  • By

  • Lingyu Pang

  • Xuefang Liu

  • Suzhen Sun

  • Fang Chen

  • Hongru Lu

  • Yakun Du

  • Xin Li

  • June 3, 2026

  • 0 min

Share

  • 1

    Tocilizumab is an IL-6 receptor inhibitor showing potential in treating pediatric Febrile Infection-Related Epilepsy Syndrome (FIRES).

  • 2

    Two pediatric patients with FIRES were treated with tocilizumab, with varying outcomes in seizure control and cognitive function.

  • 3

    Early administration of tocilizumab, ideally within three weeks of disease onset, may improve treatment outcomes in FIRES.

  • 4

    Elevated IL-6 levels were noted in the blood and cerebrospinal fluid of patients, indicating a possible autoimmune component in FIRES.

  • 5

    The study highlights the need for further research on tocilizumab's efficacy in pediatric patients with FIRES.

Original Source(s)

Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome

  • by Lingyu Pang, Xuefang Liu, Suzhen Sun, Fang Chen, Hongru Lu, Yakun Du, Xin Li

  • June 3, 2026

Related Content

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Beyond synapses non-synaptic neural microenvironment interactions remodel circuits and drive glioma progression

Handwriting Kinematics Differentiate Cognitive Impairment

“Diagnostic differentiation emerged only under tasks imposing higher cognitive-motor demands.”